Jenny McGovern
Director and Non-Clinical Group Leader Quell Therapeutics
Jenny McGovern is Senior Director of Cellular Immunology at Quell Therapeutics, where she develops regulatory T cell therapies for autoimmune and inflammatory diseases. She has held several roles at Quell since 2019, including Director and Associate Director of the Non-Clinical Group, and Senior Scientist, leading preclinical efforts in Treg therapy development.
Before joining Quell, Jenny conducted research at University College London and Imperial College London, focusing on antigen-specific regulatory T cells for multiple sclerosis and the effects of NKG2D on intestinal carcinogenesis. She earned her PhD in Medicine from UCL, with a thesis on the influence of biologic therapy on regulatory T cells, and holds a BSc Hons in Anatomical Sciences with Industrial Experience from the University of Manchester.
Seminars
- Evaluate CD19 CAR-Treg design, function, and in preliminary data
- Understand how pre-clinical results inform translational and clinical readiness
New Data
